Alembic Pharmaceuticals said the US health regulator has issued a Form 483 with four procedural observations after an inspection of its oncology injectable formulation facility at Panelav in Gujarat.

As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management after an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

The US FDA had inspected the facility located at Panelav from October 4, 2022, to October 14, 2022, Alembic Pharmaceuticals said in a regulatory filing.

"The US FDA issued a Form 483 with 4 procedural observations. None of the observations is related to data integrity, and management believes that they are addressable," it added.

The company further said it is preparing the response to the observations, which will be submitted to the US FDA within the stipulated period.